# Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg

> **NCT02550665** · PHASE3 · COMPLETED · sponsor: **Asan Medical Center** · enrollment: 176 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** donepezil

## Key facts

- **NCT ID:** NCT02550665
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-08
- **Final completion:** 2016-10
- **Target enrollment:** 176 (ACTUAL)
- **Last updated:** 2018-08-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02550665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02550665, "Optimal Dose Escalation Strategy to Successful Achievement of High Dose Donepezil 23mg". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02550665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*